Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials

NCT07456436 | Recruiting DMC

• 3 other identifiers: 19PS-24-2NCI-2026-00806P30CA014089
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study assesses patient awareness and understanding of cancer clinical trials.

Conditions

Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Outcome Measures

Primary Outcomes (1)

• Change in Baseline Survey Score

  The survey is a validated instrument (CHEKS\*) evaluated patients' knowledge and beliefs about cancer clinical trials (CCTs) before and after exposure to educational stimuli (written and video) detailing the purpose and characteristics of CCTs. The survey scores knowledge and beliefs about CCTs on a 100-point scale.The survey is collected before and after education materials are provided. The change in survey score will be analyzed. A paired t-test will be used to examine changes in CCT knowledge and Chi-Square tests of association to determine whether CCT knowledge and beliefs are associated with sociodemographic variables. \*Chung A, Donley T, Hays RD, et al. Development and evaluation of the Clinical Trial HEalth Knowledge and Beliefs Scale (CHEKS). Int J Environ Res Public Health. 2022;19(14):8660. doi:10.3390/ijerph19148660

  Through study completion, up to 1 year

Study Arms (1)

Observational

Patients review educational materials and complete surveys on study.

Other: Non-Interventional Study

Interventions

Non-Interventional Study OTHER

Non-interventional study

Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

Observational

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals with cancer in the Norris Comprehensive Cancer Center (NCCC) catchment area.

You may qualify if:

• Eligible patient participants will be:
• Black/African American, Asian/Asian American, White or Hispanic adults of any gender 21 years of age or older. Race/ethnicity will be self-reported
• Have been diagnosed any cancer type

You may not qualify if:

• Participants (patients) will be excluded if they:
• Are unable to give informed consent
• Are unable to speak English or Spanish

Sponsors & Collaborators

• University of Southern California: lead
• National Cancer Institute (NCI): collaborator
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

RECRUITING

Study Officials

• Chanita Hughes-Halbert

  University of Southern California

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2026
• First Posted: March 6, 2026
• Study Start: November 26, 2024
• Primary Completion (Estimated): November 26, 2026
• Study Completion (Estimated): November 26, 2027
• Last Updated: March 13, 2026

Record last verified: 2026-03

Locations

US (1)